A greater number of patients treated with subcutaneous TREMFYA ® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval PHILADELPHIA , Oct. 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced results from the Phase 3 GRAVITI study of TREMFYA ® (guselkumab), the first and only IL-23 inhibitor, demonstrating robust results in subcutaneous (SC) induction and maintenance therapy. The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.
1 These results are among the 14 Johnson & Johnson abstracts presented at the American College of Gastroenterology (ACG) 2024, October 25-30 . "The GRAVITI results show that induction treatment with subcutaneous guselkumab is as rapid and robust as we have seen with the IV induction, which could offer a welcome new option for Crohn's disease treatment," stated Remo Panaccione , MD, FRCPC, Study Investigator and Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary . "The one-year results of this study suggest that SC induction with guselkumab is a promising approach to help people with CD manage their symptoms and achieve meaningful endosco.
